Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)Thomas Bachelot, A Wroński, Eva Ciruelos et al.|Annals of Oncology|2019Cited by 117
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patientsJoseph Gligorov, Luis Matamala, Kyung Hae Jung et al.|European Journal of Cancer|2017Cited by 47